沈陽藥科大學(xué)制藥工程學(xué)院導(dǎo)師：劉丹 正文

[導(dǎo)師姓名]
劉丹

[所屬院校]
沈陽藥科大學(xué)

[基本信息]
導(dǎo)師姓名：劉丹
性別：女
人氣指數(shù)：1453
所屬院校：沈陽藥科大學(xué)
所屬院系：制藥工程學(xué)院
職稱：副教授
導(dǎo)師類型：碩導(dǎo)
招生專業(yè)：藥物化學(xué)、藥學(xué)（藥物化學(xué)方向）
研究領(lǐng)域：一：靶向抗腫瘤藥物的設(shè)計(jì)與研究研究方向二：藥物合成新工藝的開發(fā)研究方向三：納米前藥的設(shè)計(jì)與...

[通訊方式]
辦公電話：024-43520218
電子郵件：sammyld@163.com
通訊地址：遼寧省本溪高新技術(shù)產(chǎn)業(yè)開發(fā)區(qū)華佗大街26號沈陽藥科大學(xué)47號信箱

[個人簡述]
劉丹，女，博士，副教授。2000年畢業(yè)于沈陽藥科大學(xué)，獲化學(xué)制藥學(xué)士學(xué)位，2000年考入沈陽藥科大學(xué)藥物化學(xué)專業(yè)碩士研究生，2002年直接攻讀博士學(xué)位，2008年獲沈陽藥科大學(xué)藥物化學(xué)博士學(xué)位，2009年進(jìn)入天津天士力集團(tuán)有限公司進(jìn)行博士后研究。2005年留校任教，2011年晉升副教授，碩士研究生導(dǎo)師，2012年赴美國北卡羅來納大學(xué)教堂山分校交流訪問，現(xiàn)為制藥工程學(xué)院藥物化學(xué)教研室主任。作為課題負(fù)責(zé)人主持了國家自然科學(xué)基金項(xiàng)目2項(xiàng)，遼寧省科技廳項(xiàng)目2項(xiàng)，沈陽市科技廳項(xiàng)目1項(xiàng)，沈陽藥科大學(xué)科研專項(xiàng)基金2項(xiàng)，另外，作為項(xiàng)目骨干成員參加國家科技部重大新藥創(chuàng)制項(xiàng)目5項(xiàng)，科技部國際合作項(xiàng)目1項(xiàng)，國家自然科學(xué)基金面上項(xiàng)目5項(xiàng)。目前已在Nano Letters、ACS Applied Materials & Interfaces、European Journal of Medicinal Chemistry、Bioorganic & Medicinal Chemistry、Scientific Reports等期刊發(fā)表學(xué)術(shù)論文30余篇。

[科研工作]
近年來發(fā)表代表性論文
1.Yang Jinyu, Cheng Gaoliang,Xu Qihao, Luan Shenglin, Wang Shuxiang, LiuDan*, Zhao Linxiang*. Design, synthesis and biological evaluation of novelhydroxamic acid based histone deacetylase 6 selective inhibitors bearingphenylpyrazol scaffold as surface recognition motif. Bioorganic & MedicinalChemistry, 2018, 26(8):1418-1425. (IF=2.486)2.Shenglin Luan, Hang Zhong,Xuan Zhao, Jinyu Yang, Yongkui Jing, DanLiu*, Linxiang Zhao*. Synthesis, anticancer evaluation and pharmacokineticstudy of novel 10-O-phenyl ethers of dihydroartemisinin. European Journal ofMedicinal Chemistry. 2017, 141: 584-595. (IF=4.519)3.XiangfeiHan, Jinling Chen, Mengjuan Jiang, Na Zhang, Kexin Na, Cong Luo, Ruoshi Zhang,Mengchi Sun, Guimei Lin, Rong Zhang, Yan Ma, Dan Liu*, and Yongjun Wang*, Paclitaxel?paclitaxel prodrug nanoassembly as a versatilenanoplatform for combinational cancer therapy. ACS Applied Materials &Interfaces. 2016, 8: 33506?33513. (IF=7.504)4.Kun Li, Lei Li,Shuxiang Wang, Xiaojing Li, Tianyi Ma, DanLiu*, Yongkui Jing*, Linxiang Zhao*, Design and synthesis of novel 2-substituted11-keto-boswellic acid heterocyclic derivatives as anti-prostate cancer agentswith Pin1 inhibition ability. European Journal of Medicinal Chemistry. 2016,126: 910-919. (IF=4.519)5.Yin-bo Fan, MinHuang, Yu Cao, Ping Gong, Wen-bing Liu, Shu-yu Jin, Jia-chen Wen, Yong-kuiJing, Dan Liu*, Lin-xiang Zhao*.Usnic acid is a novel Pim-1 inhibitor with the abilities of inhibiting growthand inducing apoptosis in human myeloid leukemia cells. RSC Advances,2016,6,24091-24096. (IF= 3.108)6.Jiachen Wen, Yu Bao, Qun Niu, Jinyu Yang, Yinbo Fan, Jinhua Li, YongkuiJing*, Linxiang Zhao*, Dan Liu*. Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potenthistone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.European Journal of Medicinal Chemistry, 2016, 109: 350-359. (IF=4.519)7.Hang Zhong, Xuan Zhao, Zhizhong Zuo, Jingwei Sun, Yao Yao, Tao Wang, Dan Liu*, Linxiang Zhao*. Combating P-glycoprotein-mediated multidrug resistancewith 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells. European Journal ofMedicinal Chemistry. 2016, 108:720-729. (IF=4.519)8.Qiang Fu, YongjunWang*, Yan Ma, D. Zhang, J. K. Fallon, Xinggang Yang, Dan Liu*, Zhonggui He & Feng Liu. Programmed hydrolysis indesigning paclitaxel prodrug for nanocarrier assembly. Scientific Reports,2015, DOI: 10.1038/srep12023. (IF 5.228)9.Yongjun Wang*?, Dan Liu?, QingchuanZheng, Qiang Zhao, Hongjuan Zhang, Yan Ma, John K. Fallon, Qiang Fu, Matthew T.Haynes, Guimei Lin, Rong Zhang, Dun Wang, Xinggang Yang, Linxiang Zhao,Zhonggui He,* and Feng Liu, Disulfide bond bridge insertion turns hydrophobicanticancer prodrugs into self-assembled nanomedicines. Nano Letters, 2014, 14:5577-5583. (IF=13.592)（Author Contributions：∥Y.W. and D.L.contributed equally to this work）10.Ma, Yan? Liu, Dan? Wang, Dun Wang, YongjunFu, Qiang Fallon, John Yang, Xingang He, Zhonggui Liu, Feng*. Combinational delivery of Hydrophobic and HydrophilicAnticancer Drugs in Single Nanoemulsions to Treat MDR in Cancer. MolecularPharmaceutics, 2014, 11, 2623-2630.(IF=4.44)（Author Contributions：∥Y.M. and D.L. contributedequally to this work）

[教育背景]

沈陽藥科大學(xué)

本文來源：http://www.zhongzhouzhikong.com/syykdx/yjsds_548223.html